EGFR and colorectal cancer: Lu et al. [103] have reported the mechanism of resistance to the anti-EGFR monoclonal antibody cetuximab in colorectal cancer that had been made insensitive to this drug by exposure to subeffective doses of cetuximab over an extended period of time.